Nasdaq
$2.35▼ 1.88%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $394.3MShares out 1.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
20- 10.8Pre-market26.10.08 20:048-KKey event#●●●#●●●
Editas Medicine, Inc.Bullish
Editas Medicine has received approval to initiate a Phase 1/2 clinical trial for its hyperlipidemia candidate, EDIT-401, in Australia. The company expects to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027.…more
$2.35-1.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.9After-hours26.09.10 05:584Ownership
Editas Medicine, Inc.
Insider Daniel Scott Ory of Editas Medicine, Inc. reported a change in beneficial ownership of securities on September 8, 2026. This filing serves as a formal disclosure of insider stock activity via Form 4.…more
$2.35-1.88%vs prev closeView filingShare - 9.9After-hours26.09.10 05:243Ownership
Editas Medicine, Inc.
Daniel Ory, a director or officer of Editas Medicine, Inc., has filed a Limited Power of Attorney to fulfill reporting obligations under Section 16 of the Securities Exchange Act. This document authorizes Gilmore O'Neill, Damien Grierson, and Amy Parison to prepare and file Forms 3, 4, and 5 with the SEC on his behalf.…more
$2.35-1.88%vs prev closeView filingShare
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.8Pre-market26.10.08 20:00#●●●#●●●#●●●
Editas Medicine Receives Approval to Initiate Phase 1/2 Trial for EDIT-401…more
Editas Medicine has received approval to begin a Phase 1/2 clinical trial for its hyperlipidemia treatment candidate, EDIT-401, in Australia. The company plans to initiate patient dosing this year, with initial safety data expected in the first quarter of 2027.…more
$2.35-1.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.23Pre-market26.09.23 22:03
●●●●●●●● ●●●●● ●●●●●●
Major analysts from firms including Stifel and Guggenheim have upgraded their ratings for four stocks, including Microsoft and Editas Medicine. This report highlights the latest shifts in Wall Street's outlook on these companies.…more
$2.35-1.88%vs prev closeShareBenzinga - 9.9Pre-market26.09.09 22:00
●●●●●●●● ●●●●● ●●●●●●
Editas Medicine has granted stock options to its newly appointed Chief Medical Officer, Dr. Daniel Ory, as an inducement for his employment. This grant is a standard compensation measure following his recent appointment to the executive leadership team.…more
$2.35-1.88%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report